A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

TL-925

TL-925 is an eye drop.

OTHER

Placebo

The composition of the vehicle is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (18)

16066

Scott and Christie EyeCare Associates, Cranberry Township

24502

Piedmont Eye Center, Lynchburg

27529

Oculus Research, Garner

28451

Wilmington Eye, Leland

37072

Advancing Vision Research, Goodlettsville

37167

Advancing Vision Research, Smyrna

38119

Total Eye Care, PA, Memphis

40206

Butchertown Clinical, Louisville

47203

Pankratz Eye, Columbus

60062

Wyse Eyecare, Northbrook

85032

Cornea and Cataract Consultants of Arizona, Phoenix

90505

Nvision - Torrance, Torrance

91204

Global Research Management, Glendale

91942

Nvision - La Mesa, La Mesa

01810

Andover Eye Associates - Andover, Andover

02767

Andover Eye Associates - Raynham, Raynham

01581

NEERA - Westborough, Westborough

01801

NEERA - Woburn, Woburn

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY

NCT06225973 - A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease | Biotech Hunter | Biotech Hunter